Tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia (CML) is the
consummate success story for targeted therapy, yet relapse is a nearly inevitable …

The efficacy of second‐line treatment for chronic myeloid leukemia (CML) plays an important
role in allowing CML patients to enjoy a normal life expectancy. Four tyrosine kinase …

Despite the success with tyrosine kinase inhibitors (TKIs) in most patients with chronic
myelogenous leukemia (CML), some patients still experience resistance or intolerance and …

Studies on chronic myeloid leukemia (CML) have served as a paradigm for cancer research
and therapy. These studies involve the identification of the first cancer-associated …

Abstract The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate is highly effective in the front-
line treatment of chronic myeloid leukemia (CML) and is increasingly used in patients with …

Purpose: To investigate the potential use of accelerator mass spectrometry (AMS) in the
study of the clinical pharmacology of imatinib. Experimental Design: Six patients who were …

Molecular discoveries and clinical advances over the past few decades have made the
treatment of chronic myeloid leukemia (CML) one of the great success stories of modern …

Despite the positive results achieved by Imatinib mesylate (Imatinib) in the treatment of
chronic myeloid leukemia (CML), over the past several years, Imatinib does not eradicate …

Despite the excellent results obtained with standard-dose imatinib as first-line therapy for
chronic myeloid leukemia in the chronic phase, one third of patients do not achieve an …

Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder associated
with the Philadelphia chromosome (Ph) that arises from a reciprocal translocation between …